July 2026
The viral vectors and plasmid DNA manufacturing market size is expected to hit USD 29.82 billion by 2035 from USD 7.26 billion in 2025 with a CAGR of 15.17%.
July 2025
The global viral vectors based gene therapy for non-human primates market size is estimated to hit around USD 5.46 billion by 2034 from USD 1.3 billion in 2024, with a CAGR of 15.44%.
June 2025
The global viral vectors for non human primates market size is estimated to hit around USD 397.87 million by 2034 from USD 145.8 million in 2024, at a CAGR of 10.56%.
September 2026
The viral and non-viral vectors market was valued at USD 9.40 billion in 2025, with leading companies including Thermo Fisher Scientific Inc., Lonza Group AG, Catalent, Inc., WuXi AppTec, Oxford Biomedica plc.
June 2026
The US viral vectors and plasmid DNA manufacturing market size is valued at USD 3.30 billion in 2025 and is predicted to hit USD 11.69 billion by 2035, with a CAGR of 15.20%.
September 2026
The bacterial and viral specimen collection market reached USD 59.95 billion in 2026, featuring leading while major growth segments span Puritan Medical Products companies such as Longhorn Vaccines and Diagnostics, LLC.
September 2026
The antiviral and antimicrobial technology market is growing with demand for advanced coatings, textiles, and surfaces that prevent infection and contamination.
September 2026
The DNA-based non-viral technologies market was valued at USD 5.60 billion in 2025, with leading companies including Thermo Fisher Scientific Inc., Lonza Group AG, Bio-Rad Laboratories, Inc., Promega Corporation, Qiagen N.V.
July 2026
The global respiratory antiviral treatment market is surging, with an overall revenue growth expectation of hundreds of millions of dollars from 2026 to 2035.
June 2026
The global lentiviral vector market size is projected to surpass around USD 2,175.41 million by 2035 increasing from USD 413.21 million in 2025, with a CAGR of 18.07%.
January 2026
The viral clearance market size was estimated at USD 1.13 billion in 2025 and is expected to attain around USD 7.86 billion by 2035, with a CAGR of 21.40%.
July 2026
The next?gen delivery systems for genetic drug market is expanding with lipid nanoparticles, viral vectors, and extracellular vesicles enabling precision gene delivery.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com